(secondQuint)Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial.

 The study is a prospective, open-label, non-controlled, single-arm, multicentre phase III study.

 Patients will be followed from the time of completion of the SCGAM 01 trial until octanorm becomes commercially available in the USA, until the sponsor decides to terminate the trial, or until a patient's treatment duration of 2 years is reached (whichever occurs first).

.

 Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial@highlight

Patients will be followed from the time of completion of the SCGAM 01 trial until octanorm becomes commercially available in the USA, until the sponsor decides to terminate the trial, or until a patient's treatment duration of 2 years is reached (whichever occurs first).

